Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry

BACKGROUND: Noonan syndrome (NS) is a genetic disorder characterized by phenotypic features, including facial dysmorphology, cardiovascular anomalies, and short stature. Growth hormone (GH) has been approved by the United States Food and Drug Administration for short stature in children with NS. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Peter A, Ross, Judith, Germak, John A, Gut, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477766/
https://www.ncbi.nlm.nih.gov/pubmed/22682146
http://dx.doi.org/10.1186/1687-9856-2012-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477766/
https://www.ncbi.nlm.nih.gov/pubmed/22682146
http://dx.doi.org/10.1186/1687-9856-2012-15

Ejemplares similares